Cilostazol/Probucol

西洛他唑/普罗布考

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCilostazol/Probucol
Drug Alias NameProbucol/Cilostazol普罗布考/西洛他唑Cilostazol and Probucol普罗布考+西洛他唑西洛他唑普罗布考 +[11] 
ClassificationSmall molecules
Mechanisms of ActionPhosphodiesterase 3 inhibitors
TargetsPhosphodiesterase 3
Therapy Area/IndicationsPeripheral Arterial DiseaseCoronary Artery Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes CilostazolProbucol
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOtsuka Holdings Co Ltd
Inactive CompaniesN/A
Active IndicationsPeripheral Arterial DiseaseCoronary Artery Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A